A Rare Cause of Polyuria and Polydipsia in a Patient With Cystic Renal Disease: Maturity-Onset Diabetes of the Young Type 5

Hulya Nalcacioglua, c, Belma Haliloglub

Abstract

Hepatocyte nuclear factor-1β (HNF-1β) is a transcription factor that is responsible for the development of kidney, pancreas, liver and genitourinary tract. Affected individuals may present a variety of renal developmental abnormalities and/or maturity-onset diabetes of the young type 5 (MODY 5). Here we report a boy with autosomal recessive polycystic kidney disease (ARPKD) diagnosed in neonatal period who developed insulin-dependent diabetes at the age of 11. He presented with polyuria and polydipsia. The diagnosis of ARPKD was made in neonatal period based on the findings of large hypeechoic kidneys in antenatal ultrasound and no history of renal disease in parents. Laboratory investigations revealed hyperglycemia, glycosuria, and a reduced glomerular filtration rate (GFR). Based on autoantibody-negative diabetes and low-dose insulin requirement in addition to renal anomalies, he was suspected to have MODY 5. Genetic studies identified a known heterozygous HNF1B gene mutation (S148L) compatible with an MODY 5 phenotype. As a result, MODY 5 should be considered in children with developmental kidney disease and hyperglycemia. Also HNF-1β mutations should be suspected in patients with undefined cystic kidney disease especially when associated with other systemic findings as in our case.

Keywords: Cystic kidney disease; Maturity-onset diabetes of the young; Hepatocyte nuclear factor-1β

Introduction

Renal cystic disease may be determined during fetal life or in childhood primarily with ultrasonography [1, 2]. In cases of moderately enlarged hypeechoic kidneys (+2 SD for age) during the second and third trimester, diagnoses of autosomal recessive polycystic kidney disease (ARPKD), autosomal-dominant polycystic kidney disease (ADPKD) and transcription factor 2 (TCF-2) gene mutation related nephropathy should be considered [2, 3]. TCF-2 mutations may be involved in a wide spectrum of renal phenotypes that include renal cysts/renal hyperechogenicity, renal hypoplasia/cystic dysplasia, dysmorphic calyces, urinary tract dilatation, vesico-ureteric reflux, horseshoe kidney and renal agenesis [4-7].

Hepatocyte nuclear factor-1beta (HNF-1β) encoded by the TCF2 gene is involved in the embryonic development of liver, kidney, intestine and pancreatic islets and plays a role in the specific regulation of gene expression of these organs [4, 5]. Also, HNF-1β-regulated genes cause extra-renal abnormalities such as genital malformations (uterus agenesis, bicornuate uterus, agenesis of deferens channels, and hypospadias), abnormal liver function, hypomagnesaemia, hyperuricaemia and early-onset gout [4-6].

Renal cysts are the most commonly observed clinical feature in HNF-1β-associated disease and heterozygous mutations in HNF-1β are additionally known to be responsible for the early-onset diabetes mellitus. This combination led to the description of renal cysts and diabetes (RCAD) syndrome, also referred to as maturity-onset diabetes of the young type 5 (MODY) [7-9]. Here we report a patient with ARPKD diagnosed in neonatal period who developed insulin-dependent diabetes mellitus at the age of 11.

Case Report

An 11-year-old boy who has been followed up with a diagnosis of ARPKD at another hospital since 3 months of age applied to the nephrology department with a complaint of polyuria and polydipsia over 3 months. His parents also noted that he had fatigue and weight loss in the same period. He was the third child of consanguineous and healthy parents. His birth weight was 2,200 g after 38 weeks of gestation. At 22 weeks of gestation, fetal ultrasound revealed normal findings other than large hypeechoic kidneys. He received no specialist follow-up in the first few postnatal months.

On referral to a local nephrologist at 3 months of age, he was found to have elevated serum creatinine levels (1.9 mg/
presented with autoantibody-negative diabetes at the age of 11 years caused by a heterozygous HNF-1β mutation. MODY 5 paved the way to the accurate diagnosis.

Clinical presentation of renal involvement in utero was highly suggestive of severe polycystic kidney disease. Given increased kidney size, multiple cysts with significant renal failure and the absence of family history suggested a diagnosis of ARPKD [2, 10, 11]. However, the size of kidneys which are not enlarged relative to body size, the lack of hepatic fibrosis and portal hypertension during the follow-up mainly by ultrasound in our patient was puzzling. In ARPKD macrocysts are not routinely present at birth and kidney size stabilizes or may decrease over time and these patients do not show progressive macrocystic enlargement as in ADPKD. In addition, some patients may lack specific symptoms and results of imaging studies and liver tests may be in the normal range [10-12]. Although diabetes was diagnosed in our patient at second decade, further findings of endogenous insulin secretion (low-dose insulin requirement) and the absence of autoantibodies for diabetes and cystic kidneys prompted consideration of the diagnosis of MODY [8]. The association of polycystic kidney disease and MODY phenotype best fit RCAD, also referred to as MODY type 5 prompted genetic testing of HNF-1β [8, 9].

MODY has been described in 58% of reported HNF-1β mutation carriers, with mean age of diagnosis of 26 years [7-9]. In this context, renal involvement seems to be the first manifestation of MODY 5 and some of these features can be identified by antenatal ultrasound [5, 6, 13]. The most frequent antenatal presentation is bilateral hyperechogenic kidneys with normal or increased size [6, 14]. In our patient, bilateral enlarged hyperechogenic kidneys as the common assumption of ARPKD were already confirmed by antenatal US and the presence of associated extrarenal abnormalities as MODY 5 led us to consider the diagnostic accuracy and study direct genetic testing. Remarkably, the phenotype of bilateral hyperechogenic kidneys incidentally found during pregnancy in our patient with renal failure can be explained by HNF-1β mutation. Debramer et al [14] screened on the diagnosis of fetal bilateral hyperechogenic kidneys and found HNF-1β mutations in 29% of the 56 newborn infants. HNF-1β appears to be a main regulator in the expression of genes of which mutations are responsible for cystic kidney diseases (Nphp1, polaris, Umod, Pkd1, and Pkd2) [5]. The finding of polycystic kidneys is not predicted in patients with TCF2 mutation. Previous studies have shown that HNF-1β directly regulates Pkd1 gene expression and established a novel link between two renal cystic diseases MODY5 and ARPKD [13, 15].

Mutations in HNF-1β are inherited in an autosomal dominant pattern, although de novo mutations do occur for a third to half of all cases explaining lack of family history in many patients in the reports [4, 5, 7]. Mutations may involve heterozygous deletion of the whole gene or small mutations including missense, non-sense, frameshift and splice site mutations have been found in different domains [5, 7]. Several studies have not found a clear genotype phenotype correlation in terms of the severity and/or type of renal disease [3, 13, 16, 17]. The mutation in our case (p.S148L (c.443C>T)) was heterozygous and located in exon 2 within the pseudo-POU domain of the gene that determines the target sequence specificity of
the HNF-1β molecule. The parents had no history or clinical symptoms related to diabetes or kidney disease. We could not perform genetic analysis in any other family member due to fiscal problems. Therefore, suggesting S148L mutation in our patient to represent a de novo mutation is highly speculative.

To date, together with our case, six patients with S148 mutations have been reported with highly different phenotypes (Table 1) [3, 13, 16, 17]. It thus seems that this specific region may present a genetic hot spot for mutations in HNF-1β.

In conclusion, we present a patient with a heterozygous mutation in the HNF-1β gene resulting in a phenotype of severe renal involvement manifested at birth and early-onset diabetes with β-cell dysfunction. MODY 5 should be considered in the differential diagnosis of children with developmental kidney disease and hyperglycemia. Also HNF-1β mutations should be suspected in patients with undefined cystic kidney disease especially when associated with other systemic findings as in our case.

**Disclosure**

The authors declare that they have no potential conflicts of interest and financial disclosure.

**References**


---

**Table 1. Case Series of S148 HNF-1β Mutations**

<table>
<thead>
<tr>
<th>Kidney</th>
<th>Diabetes</th>
<th>Pancreas</th>
<th>Genital tract - other</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1* Normal kidney function</td>
<td>Neonatal diabetes</td>
<td>-</td>
<td>-</td>
<td>13</td>
</tr>
<tr>
<td>Case 2* Cystic renal disease (renal failure +), kidney transplantation at age 2 year</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13</td>
</tr>
<tr>
<td>Case 3 Renal dysplasia at birth (renal failure -)</td>
<td>Diabetes (at age 13 years)</td>
<td>-</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Case 4 Renal dysplasia at birth (renal failure -)</td>
<td>Neonatial diabetes</td>
<td>Pancreas atrophy</td>
<td>-</td>
<td>17</td>
</tr>
<tr>
<td>Case 5 Renal dysplasia at birth (renal failure -), dialysis at age 23 year</td>
<td>Diabetes (at age 13 years)</td>
<td>Pancreas atrophy</td>
<td>-</td>
<td>16</td>
</tr>
<tr>
<td>Case 6 Cystic renal disease, renal failure at birth</td>
<td>Diabetes (at age 11 years)</td>
<td>-</td>
<td>-</td>
<td>Our case</td>
</tr>
</tbody>
</table>

*Siblings.*
